In a study based on the TCGA database, Chen et al. predicted that SYT16 is a prognostic biomarker of low-grade gliomas and was found to be predominantly enriched in the neuroactive ligand-receptor interaction pathway46. Here, SYT16 is linked to central nervous system cancer.